GENESYSTEM CO., LTD. Financials Genesystem Co., Ltd.
Equities
A363250
KR7363250002
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,400 KRW | +0.16% |
|
-2.29% | -31.40% |
| Mar. 28 | Genesystem Co., Ltd. announces an Equity Buyback for KRW 3,000 million worth of its shares. | CI |
| Mar. 28 | Genesystem Co., Ltd. authorizes a Buyback Plan. | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 |
|---|---|---|
| Capitalization 1 | 78,767 | 58,004 |
| Enterprise Value (EV) 1 | 45,264 | 35,610 |
| P/E ratio | 20.7 x | -6.42 x |
| Yield | - | - |
| Capitalization / Revenue | 5.95 x | 15.9 x |
| EV / Revenue | 3.42 x | 9.75 x |
| EV / EBITDA | 17.6 x | -5.73 x |
| EV / FCF | -67,589,547 x | -7,397,438 x |
| FCF Yield | -0% | -0% |
| Price to Book | 1.79 x | 1.65 x |
| Nbr of stocks (in thousands) | 6,879 | 6,930 |
| Reference price 2 | 11,450 | 8,370 |
| Announcement Date | 3/1/22 | 3/1/23 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Net sales 1 | 1,135 | 13,258 | 13,237 | 3,653 |
| EBITDA 1 | -2,358 | 3,615 | 2,574 | -6,219 |
| EBIT 1 | -2,494 | 3,365 | 2,266 | -6,605 |
| Operating Margin | -219.78% | 25.38% | 17.12% | -180.8% |
| Earnings before Tax (EBT) 1 | -4,041 | -3,592 | 3,165 | -7,060 |
| Net income 1 | -4,041 | -2,224 | 3,551 | -8,996 |
| Net margin | -356.08% | -16.77% | 26.83% | -246.26% |
| EPS 2 | -1,828 | -588.0 | 554.0 | -1,304 |
| Free Cash Flow | - | -8,251 | -669.7 | -4,814 |
| FCF margin | - | -62.24% | -5.06% | -131.78% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 12/31/20 | 3/1/21 | 3/1/22 | 3/1/23 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Net Debt 1 | 5,466 | - | - | - |
| Net Cash position 1 | - | 5,102 | 33,502 | 22,394 |
| Leverage (Debt/EBITDA) | -2.318 x | - | - | - |
| Free Cash Flow | - | -8,251 | -670 | -4,814 |
| ROE (net income / shareholders' equity) | - | -338% | 12.6% | -22.7% |
| ROA (Net income/ Total Assets) | - | 20.1% | 4.07% | -8.99% |
| Assets 1 | - | -11,081 | 87,231 | 100,074 |
| Book Value Per Share 2 | -5,743 | 3,256 | 6,408 | 5,066 |
| Cash Flow per Share 2 | 363.0 | 2,395 | 3,726 | 2,430 |
| Capex 1 | 137 | 5,741 | 324 | 238 |
| Capex / Sales | 12.03% | 43.3% | 2.45% | 6.53% |
| Announcement Date | 12/31/20 | 3/1/21 | 3/1/22 | 3/1/23 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -31.40% | 32.52M | |
| -8.50% | 11.67B | |
| -5.68% | 8B | |
| +6.41% | 5.72B | |
| +28.78% | 5.5B | |
| -14.91% | 3.84B | |
| +10.70% | 2.66B | |
| -61.67% | 2.66B | |
| -9.24% | 2.3B | |
| +15.60% | 2.01B |
- Stock Market
- Equities
- A363250 Stock
- Financials Genesystem Co., Ltd.
